Tetrahydroisoquinoline Derivatives For The Treatment Of Red Blood

Tetrahydroisoquinoline Derivatives For The Treatment Of Red Blood Disorders And Inflammatory Diseases

Abstract: Provided herein are compounds and compositions thereof for activating nuclear factor erythroid 2-related factor 2 (Nrf2) for treating red blood cell diseases and inflammatory diseases.

Patent Information

Application #

Filing Date

11 April 2023

Publication Number

47/2023

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

SANOFI

46 avenue de la Grande Armée 75017 Paris

Inventors

1. BARBERIS, Claude

c/o Sanofi U.S. 55 Corporate Drive, Mail Code: 55A-525 Bridgewater, New Jersey 08807

2. KARAGEORGE, George

c/o Sanofi U.S. 55 Corporate Drive, Mail Code: 55A-525 Bridgewater, New Jersey 08807

3. JURCAK, John

c/o Sanofi U.S. 55 Corporate Drive, Mail Code: 55A-525 Bridgewater, New Jersey 08807

4. TERRANOVA, Kristen

c/o Sanofi U.S. 55 Corporate Drive, Mail Code: 55A-525 Bridgewater, New Jersey 08807

Specification

Documents

Application Documents

#	Name	Date
1	202317026912.pdf	2023-04-11
2	202317026912-STATEMENT OF UNDERTAKING (FORM 3) [11-04-2023(online)].pdf	2023-04-11
3	202317026912-PROOF OF RIGHT [11-04-2023(online)].pdf	2023-04-11
4	202317026912-PRIORITY DOCUMENTS [11-04-2023(online)].pdf	2023-04-11
5	202317026912-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [11-04-2023(online)].pdf	2023-04-11
6	202317026912-FORM 1 [11-04-2023(online)].pdf	2023-04-11
7	202317026912-DECLARATION OF INVENTORSHIP (FORM 5) [11-04-2023(online)].pdf	2023-04-11
8	202317026912-COMPLETE SPECIFICATION [11-04-2023(online)].pdf	2023-04-11
9	202317026912-FORM-26 [13-07-2023(online)].pdf	2023-07-13
10	202317026912-Proof of Right [09-10-2023(online)].pdf	2023-10-09
11	202317026912-FORM 3 [08-04-2024(online)].pdf	2024-04-08
12	202317026912-FORM 18 [12-09-2024(online)].pdf	2024-09-12
13	202317026912-FORM 3 [14-10-2024(online)].pdf	2024-10-14